Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts

Molecular Imaging and Biology

Volumn 17, Issue 1, 2015, Pages 94-101

  van Rij, Catharina M ^a   Frielink, Cathelijne ^a   Goldenberg, David M ^b,c   Sharkey, Robert M ^b   Franssen, Gerben M ^a   Lütje, Susanne ^a   McBride, William J ^b   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMMUNOMEDICS INC   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

Bispecific monoclonal antibody; Pretargeted immunoPET; Prostate cancer; TROP 2

Indexed keywords

BISPECIFIC ANTIBODY; CELL ADHESION MOLECULE; DOTA-TYROSYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)-GLUTAMYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)AMIDE; GLYCINE; HAPTEN; HISTAMINE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; TROP2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOTHERAPY; MALE; METABOLISM; MOUSE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; GLYCINE; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HISTAMINE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84939884802     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0772-x     Document Type: Article

References (16)

1. Beheshti M, Langsteger W, Fogelman I (2009) Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 39:396–407
2. Ravizzini G, Turkbey B, Kurdziel K et al (2009) New horizons in prostate cancer imaging. Eur J Radiol 70:212–226
3. Outwater EK, Montilla-Soler JL (2013) Imaging of prostate carcinoma. Cancer Control 20:161–176
4. Lutje S, Boerman OC, van Rij CM et al (2012) Prospects in radionuclide imaging of prostate cancer. Prostate 72:1262–1272
5. Jadvar H (2013) Molecular imaging of prostate cancer with PET. J Nucl Med 54:1685–1688
6. Hillier SM, Maresca KP, Lu G et al (2013) 99mTc-labeled small-molecule inhibitors of prostate specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 54:1369–1376
7. Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
8. van Rij CM, Lutje S, Frielink C et al (2013) Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging 40:1377–1383
9. Basu A, Goldenberg DM, Stein R (1995) The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 62:472–479
10. Stein R, Basu A, Chen S et al (1993) Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 55:938–946
11. Rossi EA, Goldenberg DM, Cardillo TM et al (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 103:6841–6846
12. 124I-labeled hapten-peptide. J Nucl Med 47:1678–1688
13. 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 9:1019–1027
14. 111In in HEPES and MES buffer. EJNMMI Res 2:4
15. Kitajima K, Murphy RC, Nathan MA (2013) Choline PET/CT for imaging prostate cancer: an update. Ann Nucl Med 27:581–591
16. Ristau BT, O’Keefe DS, Bacich DJ (2014) The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 323:272–279